The Italian firm is opening a new production line to improve process efficiency and increase its activity, and is also considering several additional investments in the region to expand its industrial capacity.
The Regional Minister for Economy, Finance and Employment, Rocío Albert, visited the company’s laboratories today, where she stressed that this business decision “fits perfectly with the strategy of supporting high value-added industrial projects that generate skilled employment and are committed to innovation.” Albert noted that 78 companies dedicated to the manufacture of pharmaceutical products operate in the Madrid Region, representing 22.1% of the national total, with a turnover of €5,106.1 million, accounting for 25.7% of Spain’s overall figure. In addition, their exports reached €7,469 million in 2024, 42.3% of the national total, showing strong growth compared to pre-pandemic levels.
“The commitment of companies such as Italfarmaco to Madrid strengthens leadership in the pharmaceutical industry and biomedicine, and consolidates municipalities such as Alcobendas as driving hubs for scientific and technical talent,” Albert emphasized. She also highlighted Madrid as an “example of institutional stability, with a competitive tax framework and an environment that is favorable to projects contributing to the strengthening of the industrial fabric, boosting innovation, and generating new opportunities for high-quality employment in high-technology sectors.”
Founded in 1938 and present in numerous international markets, Italfarmaco carries out activities in Spain focused on research and the manufacture of prescription medicines, hospital products, oncology, immunology, fertility, and the cardiovascular field. The Alcobendas plant is one of the group’s strategic facilities in Europe, with a strong export orientation and a clear focus on incorporating advanced technology into its production processes.